Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study Meeting Abstract


Authors: Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Cohen, J. B.; Roeker, L. E.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C. S.; Lewis, D. J.; Gerson, J. N.; Alencar, A. J.; Ujjani, C. S.; Flinn, I. W.; Sundaram, S.; Ma, S.; Jagadeesh, D.; Rhodes, J. M.; Taylor, J.; Abdel-Wahab, O.; Ghia, P.; Schuster, S. J.; Wang, D.; Nair, B.; Zhu, E.; Tsai, D.; Davids, M. S.; Brown, J. R.; Jurczak, W.
Abstract Title: Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
Meeting Title: 63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 138
Issue: Suppl. 1
Meeting Dates: 2021 Dec 11-14
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2021-11-23
Language: English
ACCESSION: WOS:000736398801165
DOI: 10.1182/blood-2021-147599
PROVIDER: wos
Notes: Meeting Abstract: 391 -- Hybrid meeting, also took place online -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anthony R Mato
    236 Mato
  2. Lindsey Elizabeth Roeker
    143 Roeker